Literature DB >> 26109717

Reduced neurofilament expression in cutaneous nerve fibers of patients with CMT2E.

Chiara Pisciotta1, Yunhong Bai2, Kathryn M Brennan2, Xingyao Wu2, Tiffany Grider2, Shawna Feely2, Suola Wang2, Steven Moore2, Carly Siskind2, Michael Gonzalez2, Stephan Zuchner2, Michael E Shy2.   

Abstract

OBJECTIVE: To investigate the effects of NEFL Glu396Lys mutation on the expression and assembly of neurofilaments (NFs) in cutaneous nerve fibers of patients with Charcot-Marie-Tooth disease type 2E (CMT2E).
METHODS: A large family with CMT2E underwent clinical, electrophysiologic, and skin biopsy studies. Biopsies were processed by indirect immunofluorescence (IF), electron microscopy (EM), and Western blot analysis.
RESULTS: The clinical features demonstrated intrafamilial phenotypic variability, and the electrophysiologic findings revealed nerve conductions that were either slow or in the intermediate range. All patients had reduced or absent compound muscular action potential amplitudes. Skin biopsies showed axons labeled with the axonal markers protein gene product 9.5 and α-tubulin, but not with NFs. The results of Western blot analysis were consistent with those of IF, showing reduced or absent NFs and normal expression of α-tubulin. EM revealed clusters of regenerated fibers, in absence of myelin sheath abnormalities. Both IF and EM failed to show NF aggregates in dermal axons. The morphometric analysis showed a smaller axonal caliber in patients than in controls. The study of the nodal/paranodal architecture demonstrated that sodium channels and Caspr were correctly localized in patients with CMT2E.
CONCLUSIONS: Decrease in NF abundance may be a pathologic marker of CMT2E. The lack of NF aggregates, consistent with prior studies, suggests that they occur proximally leading to subsequent alterations in the axonal cytoskeleton. The small axonal caliber, along with the normal molecular architecture of nodes and paranodes, explain the reduced velocities detected in patients with CMT2E. Our results also demonstrate that skin biopsy can provide evidence of pathologic and pathogenic abnormalities in patients with CMT2E.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Year:  2015        PMID: 26109717      PMCID: PMC4516296          DOI: 10.1212/WNL.0000000000001773

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  23 in total

1.  Myelinated nerve endings in human skin.

Authors:  Vincenzo Provitera; Maria Nolano; Angela Pagano; Giuseppe Caporaso; Annamaria Stancanelli; Lucio Santoro
Journal:  Muscle Nerve       Date:  2007-06       Impact factor: 3.217

2.  Muscle pathology without severe nerve pathology in a new mouse model of Charcot-Marie-Tooth disease type 2E.

Authors:  Hailian Shen; Devin M Barry; Jeffrey M Dale; Virginia B Garcia; Nigel A Calcutt; Michael L Garcia
Journal:  Hum Mol Genet       Date:  2011-04-14       Impact factor: 6.150

3.  Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments.

Authors:  Q Zhu; S Couillard-Després; J P Julien
Journal:  Exp Neurol       Date:  1997-11       Impact factor: 5.330

4.  HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.

Authors:  Constantin d'Ydewalle; Jyothsna Krishnan; Driss M Chiheb; Philip Van Damme; Joy Irobi; Alan P Kozikowski; Pieter Vanden Berghe; Vincent Timmerman; Wim Robberecht; Ludo Van Den Bosch
Journal:  Nat Med       Date:  2011-07-24       Impact factor: 53.440

5.  Axonal neurofilaments control multiple fiber properties but do not influence structure or spacing of nodes of Ranvier.

Authors:  Rodolphe Perrot; Pierre Lonchampt; Alan C Peterson; Joël Eyer
Journal:  J Neurosci       Date:  2007-09-05       Impact factor: 6.167

6.  Mitochondrial and axonal abnormalities precede disruption of the neurofilament network in a model of charcot-marie-tooth disease type 2E and are prevented by heat shock proteins in a mutant-specific fashion.

Authors:  Miranda L Tradewell; Heather D Durham; Walter E Mushynski; Benoit J Gentil
Journal:  J Neuropathol Exp Neurol       Date:  2009-06       Impact factor: 3.685

7.  Clinical and electrophysiological features in Charcot-Marie-Tooth disease with mutations in the NEFL gene.

Authors:  Gabriel Miltenberger-Miltenyi; Andreas R Janecke; Julia V Wanschitz; Vincent Timmerman; Christian Windpassinger; Michaela Auer-Grumbach; Wolfgang N Löscher
Journal:  Arch Neurol       Date:  2007-07

8.  Neurofilament light chain polypeptide gene mutations in Charcot-Marie-Tooth disease: nonsense mutation probably causes a recessive phenotype.

Authors:  Akiko Abe; Chikahiko Numakura; Kayoko Saito; Hiroyoshi Koide; Nobuyuki Oka; Akira Honma; Yumiko Kishikawa; Kiyoshi Hayasaka
Journal:  J Hum Genet       Date:  2009-01-16       Impact factor: 3.172

9.  Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.

Authors:  Sinéad M Murphy; David N Herrmann; Michael P McDermott; Steven S Scherer; Michael E Shy; Mary M Reilly; Davide Pareyson
Journal:  J Peripher Nerv Syst       Date:  2011-09       Impact factor: 3.494

10.  Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton.

Authors:  Gian Maria Fabrizi; Tiziana Cavallaro; Chiara Angiari; Ilaria Cabrini; Federica Taioli; Giovanni Malerba; Laura Bertolasi; Nicoló Rizzuto
Journal:  Brain       Date:  2006-10-18       Impact factor: 13.501

View more
  8 in total

1.  Schwann cell transcript biomarkers for hereditary neuropathy skin biopsies.

Authors:  John Svaren; John J Moran; Xingyao Wu; Riccardo Zuccarino; Chelsea Bacon; Yunhong Bai; Raghu Ramesh; Laurie Gutmann; Daniel M Anderson; Derek Pavelec; Michael E Shy
Journal:  Ann Neurol       Date:  2019-04-22       Impact factor: 10.422

2.  Muscle spindle alterations precede onset of sensorimotor deficits in Charcot-Marie-Tooth type 2E.

Authors:  E Villalón; M R Jones; C Sibigtroth; S J Zino; J M Dale; D S Landayan; H Shen; D D W Cornelison; M L Garcia
Journal:  Genes Brain Behav       Date:  2016-10-11       Impact factor: 3.449

3.  Charcot-Marie-Tooth disease type 2CC due to NEFH variants causes a progressive, non-length-dependent, motor-predominant phenotype.

Authors:  Menelaos Pipis; Andrea Cortese; James M Polke; Roy Poh; Jana Vandrovcova; Matilde Laura; Mariola Skorupinska; Arnaud Jacquier; Raul Juntas-Morales; Philippe Latour; Philippe Petiot; Guilhem Sole; Yves Fromes; Sachit Shah; Julian Blake; Byung-Ok Choi; Ki Wha Chung; Tanya Stojkovic; Alexander M Rossor; Mary M Reilly
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-09-13       Impact factor: 13.654

4.  N98S mutation in NEFL gene is dominantly inherited with a phenotype of polyneuropathy and cerebellar atrophy.

Authors:  Yi Yang; Li-Qiang Gu; William B Burnette; Jun Li
Journal:  J Neurol Sci       Date:  2016-04-09       Impact factor: 3.181

5.  NEFL N98S mutation: another cause of dominant intermediate Charcot-Marie-Tooth disease with heterogeneous early-onset phenotype.

Authors:  José Berciano; Kristien Peeters; Antonio García; Tomás López-Alburquerque; Elena Gallardo; Arantxa Hernández-Fabián; Ana L Pelayo-Negro; Els De Vriendt; Jon Infante; Albena Jordanova
Journal:  J Neurol       Date:  2015-12-08       Impact factor: 4.849

6.  Genetic and clinical characteristics of NEFL-related Charcot-Marie-Tooth disease.

Authors:  Alejandro Horga; Matilde Laurà; Zane Jaunmuktane; Nivedita U Jerath; Michael A Gonzalez; James M Polke; Roy Poh; Julian C Blake; Yo-Tsen Liu; Sarah Wiethoff; Conceição Bettencourt; Michael Pt Lunn; Hadi Manji; Michael G Hanna; Henry Houlden; Sebastian Brandner; Stephan Züchner; Michael Shy; Mary M Reilly
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-05-13       Impact factor: 10.154

Review 7.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

8.  Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy.

Authors:  Markus T Sainio; Emil Ylikallio; Laura Mäenpää; Jenni Lahtela; Pirkko Mattila; Mari Auranen; Johanna Palmio; Henna Tyynismaa
Journal:  Neurol Genet       Date:  2018-06-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.